Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Electrochemotherapy vs narrow excision margins for high‑risk primary cutaneous melanoma
2018-003531-30Phase 2Terminated
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bleomycin in cutaneous melanoma (CM) (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Rate of grade ≥3 complications. Started May 2021; status: terminated.
02
Drugs
bleomycin
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2018-003531-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003531-30.